H.C. Wainwright lowered the firm’s price target on Curis to $26 from $51 and keeps a Buy rating on the shares following the Q4 report. The analyst now only considers the CNS lymphoma indication for emavusertib in non-Hodgkin’s lymphoma in the valuation.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CRIS:
